SAB Biotherapeutics, Inc. (NASDAQ:SABS) Receives $9.33 Consensus Price Target from Brokerages

Shares of SAB Biotherapeutics, Inc. (NASDAQ:SABS) have earned an average recommendation of “Moderate Buy” from the five brokerages that are currently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, three have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $9.3333.

SABS has been the topic of several research reports. Leerink Partnrs upgraded shares of SAB Biotherapeutics to a “strong-buy” rating in a research report on Wednesday, September 17th. Weiss Ratings restated a “sell (d-)” rating on shares of SAB Biotherapeutics in a research report on Tuesday. Leerink Partners started coverage on SAB Biotherapeutics in a research note on Wednesday, September 17th. They set an “outperform” rating and a $7.00 price target for the company. Wall Street Zen upgraded SAB Biotherapeutics to a “sell” rating in a research report on Saturday, September 20th. Finally, Chardan Capital reissued a “buy” rating and set a $12.00 price objective on shares of SAB Biotherapeutics in a report on Friday, September 19th.

SAB Biotherapeutics Trading Down 9.1%

Shares of SAB Biotherapeutics stock opened at $3.10 on Friday. SAB Biotherapeutics has a 1 year low of $1.00 and a 1 year high of $6.60. The firm has a market cap of $32.27 million, a PE ratio of -0.78 and a beta of 0.60. The company has a debt-to-equity ratio of 0.27, a current ratio of 0.87 and a quick ratio of 0.87. The company has a 50 day simple moving average of $2.57 and a two-hundred day simple moving average of $2.22.

Institutional Investors Weigh In On SAB Biotherapeutics

A hedge fund recently bought a new stake in SAB Biotherapeutics stock. HB Wealth Management LLC acquired a new stake in shares of SAB Biotherapeutics, Inc. (NASDAQ:SABS) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 307,500 shares of the company’s stock, valued at approximately $618,000. HB Wealth Management LLC owned about 2.95% of SAB Biotherapeutics at the end of the most recent quarter. 7.82% of the stock is currently owned by institutional investors and hedge funds.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.